The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
 
Swetha Kambhampati
No Relationships to Disclose
 
Monica Saumoy
No Relationships to Disclose
 
Stacy Pak
No Relationships to Disclose
 
L Elizabeth Budde
Consulting or Advisory Role - BeiGene; Kite/Gilead; Novartis; Roche/Genentech
Research Funding - Amgen; AstraZeneca; Merck; MustangBio
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia.
Travel, Accommodations, Expenses - Kite/Gilead; Roche/Genentech
 
Matthew Genyeh Mei
Honoraria - CTI; EUSA Pharma; Janssen
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Incyte
Research Funding - BeiGene (Inst); Celgene/Bristol-Myers Squibb (Inst); Epizyme (Inst); Incyte (Inst); MorphoSys (Inst); TG Therapeutics (Inst)
 
Leslie Popplewell
Honoraria - ADC Therapeutics; Kite, a Gilead company
 
Yi-Ping Wen
No Relationships to Disclose
 
Stephen J. Forman
Stock and Other Ownership Interests - Lixte Biotechnology; MustangBio
Consulting or Advisory Role - Alimera Sciences; Lixte Biotechnology; MustangBio; MustangBio
Research Funding - MustangBio
Patents, Royalties, Other Intellectual Property - MustangBio
 
Larry W. Kwak
Stock and Other Ownership Interests - InnoLife; Pepromene; TheraTest Laboratories
Honoraria - Genentech/Roche; Teva
Consulting or Advisory Role - CJ Healthcare; Enzychem Lifesciences; InnoLife; Pepromene; Sellas Life Sciences
Research Funding - InnoLife; Pepromene
Travel, Accommodations, Expenses - Celltrion
 
Steven T. Rosen
Stock and Other Ownership Interests - Exicure; January Therapeutics; Pepromene; Trillium Therapeutics
Honoraria - Celgene
Consulting or Advisory Role - Apobiologix; Apotex; Exicure; NeoGenomics Laboratories; Pepromene; PharmaGene; Trillium Therapeutics; Verastem
Speakers' Bureau - Abbvie; Celgene; Global Education Group; Paradigm
Research Funding - Celgene
 
Alex Francisco Herrera
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Genmab; Karyopharm Therapeutics; Merck; Regeneron; Seagen; Takeda; Tubulis GmbH
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Nikhil Thiruvengadam
No Relationships to Disclose